Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 4% of the time (217 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-04-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: as determineddetermined bymedicalacuteor equal
  Phrases that lowered it: participantritonavirweeksthe pharmacokineticsregimen
• Collaborators: 3 (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Sponsor's past trials: 1447 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 26.7% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Sponsor's past termination rate: 8.0% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 77 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 97.9% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: not given (raises risk) · Who can join
• Number of arms: 4 (lowers risk) · Design
• Maximum age: 17 (raises risk) · Who can join
• Blinding: none (lowers risk) · Design
• Sponsor type: government (lowers risk) · Sponsor's track record
• Responsible party: sponsor (lowers risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB NCT01751568 · started 2014 · scored riskier than 24% of active trials completed
• Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV NCT02906007 · started 2017 · scored riskier than 33% of active trials completed
• Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB) NCT01404312 · started 2012 · scored riskier than 15% of active trials completed
• Tuberculosis Clinical Trials Consortium Study 35 NCT03730181 · started 2019 · scored riskier than 14% of active trials completed
• Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals NCT04272242 · started 2021 · scored riskier than 17% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.